- Home
- GUTS vs PEPG Comparison
GUTS vs PEPG Comparison
Compare GUTS & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- PEPG
- Stock Information
- Founded
- GUTS 2010
- PEPG 2018
- Country
- GUTS United States
- PEPG United States
- Employees
- GUTS N/A
- PEPG N/A
- Industry
- GUTS
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- PEPG Health Care
- Exchange
- GUTS NYSE
- PEPG Nasdaq
- Market Cap
- GUTS 58.8M
- PEPG 45.5M
- IPO Year
- GUTS 2024
- PEPG 2022
- Fundamental
- Price
- GUTS $1.58
- PEPG $1.10
- Analyst Decision
- GUTS Buy
- PEPG Buy
- Analyst Count
- GUTS 1
- PEPG 3
- Target Price
- GUTS $10.00
- PEPG $7.67
- AVG Volume (30 Days)
- GUTS 930.5K
- PEPG 271.6K
- Earning Date
- GUTS 08-13-2025
- PEPG 08-07-2025
- Dividend Yield
- GUTS N/A
- PEPG N/A
- EPS Growth
- GUTS N/A
- PEPG N/A
- EPS
- GUTS N/A
- PEPG N/A
- Revenue
- GUTS $60,000.00
- PEPG N/A
- Revenue This Year
- GUTS N/A
- PEPG N/A
- Revenue Next Year
- GUTS N/A
- PEPG N/A
- P/E Ratio
- GUTS N/A
- PEPG N/A
- Revenue Growth
- GUTS N/A
- PEPG N/A
- 52 Week Low
- GUTS $0.87
- PEPG $0.88
- 52 Week High
- GUTS $4.92
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- GUTS 42.52
- PEPG 29.69
- Support Level
- GUTS $1.54
- PEPG $1.10
- Resistance Level
- GUTS $1.82
- PEPG $1.49
- Average True Range (ATR)
- GUTS 0.18
- PEPG 0.10
- MACD
- GUTS -0.07
- PEPG -0.04
- Stochastic Oscillator
- GUTS 5.06
- PEPG 0.00
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.